Literature DB >> 24957216

Is evening dosing of antihypertensive therapy ready for prime time?

John M Flack1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24957216      PMCID： PMC8032060          DOI： 10.1111/jch.12355

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  11 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J A Staessen; L Thijs; R Fagard; E T O'Brien; D Clement; P W de Leeuw; G Mancia; C Nachev; P Palatini; G Parati; J Tuomilehto; J Webster
Journal:  JAMA       Date:  1999-08-11       Impact factor: 56.272

3.  Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep.

Authors:  Iddo Z Ben-Dov; Jeremy D Kark; Drori Ben-Ishay; Judith Mekler; Liora Ben-Arie; Michael Bursztyn
Journal:  Hypertension       Date:  2007-03-26       Impact factor: 10.190

4.  Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Chronobiol Int       Date:  2010-09       Impact factor: 2.877

5.  The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy.

Authors:  Atsushi Hoshino; Takeshi Nakamura; Hiroaki Matsubara
Journal:  Clin Exp Hypertens       Date:  2010-09-09       Impact factor: 1.749

6.  Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension.

Authors:  Robert H Fagard; Hilde Celis; Lutgarde Thijs; Jan A Staessen; Denis L Clement; Marc L De Buyzere; Dirk A De Bacquer
Journal:  Hypertension       Date:  2007-11-26       Impact factor: 10.190

7.  A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.

Authors:  Mahboob Rahman; Tom Greene; Robert A Phillips; Lawrence Y Agodoa; George L Bakris; Jeanne Charleston; Gabriel Contreras; Francis Gabbai; Leena Hiremath; Kenneth Jamerson; Cynthia Kendrick; John W Kusek; James P Lash; Janice Lea; Edgar R Miller; Stephen Rostand; Robert Toto; Xulei Wang; Jackson T Wright; Lawrence J Appel
Journal:  Hypertension       Date:  2012-11-19       Impact factor: 10.190

8.  Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension.

Authors:  Ramón C Hermida; Diana E Ayala; José R Fernández; Carlos Calvo
Journal:  Hypertension       Date:  2007-07-16       Impact factor: 10.190

Review 9.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

Review 10.  Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial.

Authors:  Barry L Carter; Elizabeth A Chrischilles; Gary Rosenthal; Brian M Gryzlak; Eric L Eisenstein; Mark W Vander Weg
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-12-24       Impact factor: 3.738
View more
  1 in total

1.  Ethical complexities in standard of care randomized trials: A case study of morning versus nighttime dosing of blood pressure drugs.

Authors:  Scott Y H Kim; Franklin G Miller
Journal:  Clin Trials       Date:  2015-09-22       Impact factor: 2.486
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.